➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Johnson and Johnson
Mallinckrodt
Harvard Business School
Express Scripts

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for MN-166

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug MN-166?

MN-166 is an investigational drug.

There have been 11 clinical trials for MN-166. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2019.

The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Alcohol Abuse and Alcoholism (NIAAA).

There are seven hundred and seventeen US patents protecting this investigational drug and seven international patents.

Recent Clinical Trials for MN-166
TitleSponsorPhase
Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDSMediciNovaPhase 2
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSMediciNovaPhase 2/Phase 3
Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy VolunteersMediciNovaPhase 1

See all MN-166 clinical trials

Clinical Trial Summary for MN-166

Top disease conditions for MN-166
Top clinical trial sponsors for MN-166

See all MN-166 clinical trials

US Patents for MN-166

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MN-166   Start Trial Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
MN-166   Start Trial Therapeutic approaches for treating Parkinson's disease Pharnext (Issy les Moulineaux, FR)   Start Trial
MN-166   Start Trial Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells Selecta Biosciences, Inc. (Watertown, MA)   Start Trial
MN-166   Start Trial Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag The Catholic University of America (Washington, DC)   Start Trial
MN-166   Start Trial Ultra-pure agonists of guanylate cyclase C, method of making and using same SYNERGY PHARMACEUTICALS, INC. (New York, NY)   Start Trial
MN-166   Start Trial Melanocortin-1 receptor-specific cyclic hexapeptides Palatin Technologies, Inc. (Cranbury, NJ)   Start Trial
MN-166   Start Trial Pyrazolopyridines and pyrazolopyrimidines Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MN-166

Drugname Country Document Number Estimated Expiration Related US Patent
MN-166 Canada 2961033 2034-09-11   Start Trial
MN-166 European Patent Office 3192791 2034-09-11   Start Trial
MN-166 Japan WO2016039408 2034-09-11   Start Trial
MN-166 World Intellectual Property Organization (WIPO) 2016039408 2034-09-11   Start Trial
MN-166 Australia 2012222348 2031-03-01   Start Trial
MN-166 Australia 2012222351 2031-03-01   Start Trial
MN-166 Australia 2013224959 2031-03-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Johnson and Johnson
Mallinckrodt
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.